What is CTP-656 and why is Vertex acquiring it?

CTP-656 is an investigational drug that acts as a CFTR potentiator. Vertex is acquiring it to strengthen its pipeline of treatments for cystic fibrosis, with the goal of developing new combination therapies that can be taken once daily and target the underlying cause of the disease.

What is the financial commitment for this acquisition?

Vertex has agreed to an initial payment of $160.0 million to Concert Pharmaceuticals. Additionally, there are potential milestone payments of up to $90 million contingent upon regulatory approval in the U.S. and securing reimbursement in the UK, Germany, or France.

Are there any conditions that need to be met for the acquisition to be completed?

Yes, the closing of the asset purchase agreement is subject to several customary conditions. These include approval by Concert Pharmaceuticals' stockholders, clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and the absence of any material adverse effects or governmental actions that would prevent the transaction.

What other assets is Vertex acquiring from Concert Pharmaceuticals?

In addition to CTP-656, Vertex is also acquiring Concert's other CF research and preclinical programs that are related to CTP-656, further enhancing Vertex's capabilities in the cystic fibrosis space.

VRTX 8-K: Material Agreements

Summary

Vertex Pharmaceuticals Inc. (VRTX) announced on March 6, 2017, that it has entered into a material definitive agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, from Concert Pharmaceuticals, Inc. for an initial payment of $160.0 million. This acquisition is a strategic move to bolster Vertex's pipeline of CFTR modulators, aiming to develop future once-daily combination therapies that address the underlying cause of cystic fibrosis.

Key Highlights

1Vertex Pharmaceuticals Inc. to acquire CTP-656, an investigational CFTR potentiator, from Concert Pharmaceuticals, Inc.
2Initial payment for the asset purchase agreement (APA) is $160.0 million.
3Potential for additional milestone payments of up to $90 million tied to regulatory approval in the U.S. and reimbursement in select European countries.
4CTP-656 is intended to be part of future combination regimens for cystic fibrosis treatment.
5The transaction is subject to customary closing conditions, including Concert Pharmaceuticals' stockholder approval and antitrust review (Hart-Scott-Rodino Act).
6The acquisition aims to enhance Vertex's leadership in cystic fibrosis treatment by expanding its portfolio of CFTR modulators.
7Vertex also acquires Concert's other CF research and preclinical programs related to CTP-656.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Mar 6, 2017)

Summary

Key Highlights

Frequently Asked Questions